Provided by INmune Bio Primary and secondary resistance to therapy is a defining characteristic of progressive cancer in man. Patients and their clinical teams repeat the cycle of treatment, remission, relapse and retreatment until an effective therapy is found or the patien … Read More »

Contributed by: Matt Giegerich, CEO and Shaun Urban, President, The Inception Company Read the full article. https://www.pharmavoice.com/digital-edition/march-2019/#11 When two veteran healthcare advertising executives decide to rejoin forces, the natural — and expected — as … Read More »

Executives reflect on the major shifts in the industry in the last 15 years and the evolving market dynamics that will impact global communication. Watch the video now http://bit.ly/InceptionMar2019 Key points: Technology, digital, and data are driving change. The compressio … Read More »

Contributed by: Srini Shankar, Vice President, Life Sciences, Cognizant Read full article http://bit.ly/0219-RedZone It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote f … Read More »

See the results of a Forrester study on digital transformation http://bit.ly/0219-Executive Winning in today’s digital era requires more than just apps and a website. Fusing an enterprise for success in the digital era requires companies to seamlessly collaborate across the … Read More »

75% of Americans seek medical information online at least once a month—and yet, just 11% of clinical trials implement social-media efforts to recruit participants. Perhaps consequently, nearly half of all clinical trials fail to meet their target enrollment numbers. There is … Read More »

That consumers are engaged with their own healthcare more now than ever before might make it all too easy to overlook how deeply their modes of engagement differ from one another. It sounds logical to assume that general engagement with information would reliably predict eng … Read More »

Download infographic now http://bit.ly/LMS-ICON Establishing a training plan for all site and study staff is standard procedure for every clinical study. For regulatory compliance, sponsors need to track and provide documented evidence that allocated training has been comple … Read More »

True patient-centricity—one of the biggest healthcare buzzwords for some time—now calls for accessing the other people central to the patient: their caregivers. But these personalities, who are not just present throughout the patient experience but display a range of emotion … Read More »

Download now http://bit.ly/CDISC-ICON This recent case study by ICON outlines a project for a big pharma company. It provides advice and demonstrates the expertise needed to deliver a seamless solution for a multiple indication compound, which included 36 legacy studies. Key … Read More »

As part of its leading-edge trends reports, Syneos HealthTM has released a comprehensive analysis of currents in healthcare and what will be their tidal impact on the industry landscape. As the only end-to-end biopharmaceuticals solutions organization, Syneos Health consulte … Read More »

Instant download of paper http://bit.ly/DrugSafetyRWE A renewed focus on drug safety has emerged with the increased number of approved drugs, greater availability of information, and more direct involvement of patients in their treatments. Evidera’s latest paper covers the n … Read More »

Instant download of paper http://bit.ly/patient-perspective Have you been told by the U.S. Food and Drug Administration (FDA) to include the patient’s perspective about treatment benefit in your drug development program? If so, were you prepared to provide it? Evidera’s rece … Read More »

Our latest issue’s SpeakOut article outlines how a Cross-Trial SaaS Solution can improve your safety notifications process. Topics covered include: Cost Reduction Time Savings Greater Audit Compliance and Increased Transparency Reduced Liability The Risk of Waiting If this i … Read More »

Evidera recently wrote a paper comparing two common types of NMA approaches to reimbursement for treatments. When considering potential reimbursement of a new treatment, Health Technology Assessment (HTA) bodies worldwide need to evaluate how the product’s clinical effects c … Read More »

Have you ever hoped there was a better way to gain insights into the physicians your reps are calling on? Even no-see docs? A promising new technology offers this very solution to a nagging problem. IQcentRx, LLC, recently announced the introduction of Call-IQ, a sales force … Read More »

Evidera recently wrote an article on utilizing Machine Learning and Big Data to achieve better results. This article reviews applications that increase efficiency and allow more convincing value demonstration, broadly following a product’s lifecycle from drug discovery to dr … Read More »

Aptus Health has provided a case study on a successful Market Access Pull-Through Program. Here is a summary of the document. To capitalize on its brands’ favorable formulary positioning, we helped our client develop a Market Access Pull-Through Program (MAPP) powered by Apt … Read More »

In this white paper, you will learn how clinical trial simulation (CTS) can support early market access planning by predicting a range of feasible trial results of a new treatment that can be fed into an economic model, making it possible to anticipate challenges to the econ … Read More »

Specialty medications, which have emerged as important new treatment options for complex diseases like oncology, rheumatology and neurology, now represent approximately 50% of the overall pharmaceutical market spend, according to the report, Medicine Use and Spending in the … Read More »